Daily tabletFDA-approved
Wegovy® pill
Semaglutide in a once-daily oral tablet with a fasting routine.
Learn MoreWeight Management · Oral GLP-1
Real weight loss. One pill, once a day.
Orforglipron · once-daily oral tablet · by Eli Lilly
Foundayo™ (orforglipron) is the FDA-approved oral GLP-1 that helps eligible adults lose meaningful weight — no injections, no special fasting window, just one tablet a day guided by a licensed provider.
- Clinically studied weight-loss results — see the data below
- Once-daily tablet, with or without food
- Provider-guided titration from 0.8 mg up to 17.2 mg when appropriate
Prescription required. Foundayo™ is used with a reduced-calorie diet and increased physical activity. Individual results vary.
1 / 2
Brand-name Foundayo™
One tablet. Once a day.
Brand-name Foundayo™ by Eli Lilly, prescribed online and shipped to your door through licensed pharmacy partners.
- Type
- Oral GLP-1 tablet
- Frequency
- Once daily
- Food
- With or without
- Status
- FDA-approved
- Manufacturer
- Eli Lilly
Designed for flexibility
Fits into your day, not the other way around
A GLP-1 that behaves like an ordinary pill — take it with breakfast, at your desk, or after a walk.
No injections
A small tablet, once a day.
No fasting window
Take it with or without food, at any time.
No refrigeration
Store at room temperature — travel-friendly.
No special morning ritual
Fits alongside your other medications.
Clinical trial highlight
11.1%
average body-weight reduction at 17.2 mg at Week 72 in Trial 1, versus 2.1% with placebo. See the data
Why Foundayo™
How a once-daily pill supports weight loss
Orforglipron is a small-molecule GLP-1 receptor agonist — the same receptor as injectable GLP-1s, in a form the gut absorbs without special handling.
Take one tablet daily
At a consistent time that suits you — with or without food.
Activates GLP-1 receptors
In the brain, gut, and pancreas — the pathway that regulates appetite and fullness.
Quiets hunger, extends fullness
Gastric emptying slows and hunger signals settle, so smaller portions feel natural.
Supports weight loss with diet and exercise
Alongside a reduced-calorie eating pattern and increased physical activity.
Clinical results
Meaningful weight reduction in a once-daily pill
In Trial 1 (ATTAIN-1), adults with obesity — or overweight with a weight-related condition — taking Foundayo™ 17.2 mg lost an average of 11.1% of body weight at Week 72, versus 2.1% with placebo, alongside a reduced-calorie diet and increased physical activity.
17.2 mg dose
11.1%
average body-weight reduction at Week 72 (Trial 1).*
Placebo
2.1%
average body-weight reduction at Week 72 in the same trial.*
Dose-dependent results at Week 72
- 5.5 mg−7.4%
- 9 mg−8.3%
- 17.2 mg−11.1%
- Placebo−2.1%
*Trial 1 (ATTAIN-1): 72-week, randomized, placebo-controlled study of orforglipron in adults with obesity, or overweight plus a weight-related condition, alongside a reduced-calorie diet and increased physical activity. Treatment-regimen estimand. Individual results vary; no specific outcome is guaranteed.
Dosing
Start low. Increase gradually.
Foundayo™ starts at 0.8 mg once daily and steps up with at least 30 days between increases. Your provider decides whether — and how far — to increase based on response and tolerability.
Starting
0.8 mg
once daily
Step 1
2.5 mg
once daily
Step 2
5.5 mg
once daily
Step 3
9 mg
once daily
Step 4
14.5 mg
once daily
Maximum
17.2 mg
once daily
Allow at least 30 days between dose increases. Not every patient needs the highest dose.
Your oral options
Foundayo™ vs Wegovy® pill
Two FDA-approved once-daily GLP-1 tablets — different molecules, different daily routines.
| Foundayo™ | Wegovy® pill | |
|---|---|---|
| Active ingredient | Orforglipron (small molecule) | Semaglutide (peptide) |
| Frequency | Once daily | Once daily |
| Food & timing | Any time, with or without food | Empty stomach, ≤4 oz water, wait 30 min |
| Receptors | GLP-1 | GLP-1 |
| Dose range | 0.8–17.2 mg | 1.5–25 mg |
| Manufacturer | Eli Lilly | Novo Nordisk |
Curious about the semaglutide tablet? Learn about the Wegovy® pill.
The process
From assessment to ongoing support
Personalized care, every step of the way.
1.
Complete your online visit
Share your health history and goals from home — about 10 minutes.
2.
Provider reviews and prescribes if appropriate
A licensed provider decides whether Foundayo™ — or another option — fits you.
3.
Transparent self-pay pricing
Your total cost is confirmed before you commit — no insurance, no surprise bills.
4.
Shipped to your door
Brand-name Foundayo™ ships discreetly through licensed pharmacy partners.
5.
Ongoing support
Dose adjustments, check-ins, and real people who care.
Severe gastrointestinal reactions
Nausea, vomiting, and diarrhea can be severe, especially around dose increases. Tell your provider if symptoms don't ease.
Acute kidney injury
Vomiting or diarrhea can cause dehydration and worsen kidney function; stay hydrated.
Gallbladder disease
Gallstones and gallbladder inflammation have been reported; watch for upper-abdominal pain, fever, or yellowing of the skin.
Pancreatitis
Stop use and seek care for severe, persistent abdominal pain, with or without vomiting, that may radiate to the back.
Hypoglycemia
Risk is higher when used with insulin or sulfonylureas; know the signs of low blood sugar.
Oral contraceptive interaction
Foundayo™ can reduce the effectiveness of oral hormonal contraceptives. Switch to a non-oral method, or add a barrier method, for 30 days after starting and for 30 days after each dose escalation.
Severe allergic reactions
Stop use and get emergency help for swelling, trouble breathing, rapid heartbeat, or severe rash.
Pregnancy, mood & other medications
Do not use if pregnant or planning pregnancy. Report depression or suicidal thoughts, and tell your provider about every medication you take.
Common side effects
Nausea, diarrhea, vomiting, constipation, abdominal pain, decreased appetite, indigestion, headache, and dizziness.
Provider-guided
A short checklist before your first tablet.
Your provider reviews your BMI and weight-related conditions, personal and family thyroid history, pancreatitis and gallbladder history, kidney function, contraception, current medications, and pregnancy plans before prescribing Foundayo™.
Questions
Foundayo™ FAQ
Both are FDA-approved oral GLP-1 medications, but Foundayo™ (orforglipron) is a non-peptide small molecule. It's taken once daily at any time, with or without food, and needs no fasting window. The Wegovy® pill (semaglutide) is a peptide that must be taken on an empty stomach with a small amount of water followed by a 30-minute wait.
In Trial 1 (ATTAIN-1), adults on the 17.2 mg dose lost an average of 11.1% of body weight at Week 72, versus 2.1% for placebo, alongside a reduced-calorie diet and increased physical activity. Lower doses produced smaller reductions (7.4% at 5.5 mg; 8.3% at 9 mg). Individual results vary and no specific outcome is guaranteed.
Treatment starts at 0.8 mg once daily and steps up through 2.5 mg, 5.5 mg, 9 mg, 14.5 mg, and 17.2 mg, with at least 30 days between increases. Your provider decides whether — and how far — to increase based on your response and tolerability.
No. Take one tablet once daily at a consistent time that suits you, with or without food. There's no water-volume restriction and no waiting period before eating or taking other medications.
Yes. Foundayo™ can reduce how well oral hormonal contraceptives work. Switch to a non-oral contraceptive method, or add a barrier method, for 30 days after starting Foundayo™ and for 30 days after each dose increase. Your provider will review this with you.
Graceland Wellness is fully cash-pay with transparent self-pay pricing confirmed before you commit — no insurance, no copays, no surprise bills. Medication ships directly to your door through licensed pharmacy partners.
Nausea, diarrhea, vomiting, constipation, abdominal pain, decreased appetite, indigestion, headache, and dizziness. These are most noticeable around dose increases and often ease with time. Serious risks are described in the safety section above.
Explore more treatments
Other FDA-approved weight-management options
Weekly injectionFDA-approved
Wegovy® pen
Semaglutide, a GLP-1-only injection with a higher-dose HD option for eligible patients.
Learn MoreWeekly injectionFDA-approved
Zepbound®
Tirzepatide, a dual GIP/GLP-1 injection in a single-dose pen.
Learn MoreWeekly injectionFDA-approved
Zepbound® KwikPen®
The same tirzepatide in a multi-dose pen — four weekly doses per device.
Learn MoreGet started
One pill a day. A plan built around you.
Take a private assessment and a licensed provider will tell you whether Foundayo™ — or another option — fits your history, routine, and goals.
Prescription required. Foundayo™ is a trademark of Eli Lilly and Company; Wegovy® is a registered trademark of Novo Nordisk A/S. Graceland Wellness is not affiliated with either manufacturer. Transparent self-pay pricing; medication ships directly to your door.